Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases

Published on Sep 1, 2020in Drug Safety5.606
· DOI :10.1007/S40264-020-00946-Z
Jette A. van Lint1
Estimated H-index: 1
Naomi T. Jessurun6
Estimated H-index: 6
+ 9 AuthorsBart J F van den Bemt24
Estimated H-index: 24
INTRODUCTION Although the burden of adverse drug reactions (ADRs) has a significant impact on patients' quality of life, thorough knowledge about patients' perspectives on the burden of ADRs attributed to biologics is lacking. OBJECTIVES This study was conducted to gain insight into the patient burden of ADRs experienced with biologic use. METHODS The Dutch Biologic Monitor is a prospective, multicentre, event monitoring cohort system including information collected by web-based questionnaires from patients using biologics, mainly for immune-mediated inflammatory diseases (IMIDs). Patients were asked to complete bimonthly questionnaires on biologics used, indication for the biologic, experienced ADRs, consequences of ADRs and burden on a five-point Likert-type scale, ranging from 1 (no burden) to 5 (very high burden). We assessed potential factors associated with patient-reported burden of ADRs. RESULTS A total of 1355 patients completed 6293 questionnaires between 1 January 2017 and 1 May 2019. Almost half of the patients (665 patients, 49%), 69% with rheumatic diseases and 31% with other diseases, collectively reported 1720 unique ADRs. Infections and musculoskeletal complaints were the most burdensome ADRs and injection-site reactions were the least burdensome. ADRs leading to healthcare professional contact were more burdensome than ADRs without healthcare professional contact. Smoking, respiratory and psychiatric comorbidities were associated with higher burden of ADRs. Crohn's disease, use of adalimumab and use of sulfasalazine as combination therapy were associated with lower burden of ADRs. CONCLUSIONS The patient perspective gives important insights into the burden of ADRs experienced with biologics. This information could be used by healthcare professionals to optimise treatment with biologics.
📖 Papers frequently viewed together
#1L. KosseH-Index: 2
#2Naomi T. JessurunH-Index: 6
Last. Michael T. Nurmohamed (VUmc: VU University Medical Center)H-Index: 69
view all 7 authors...
OBJECTIVES: Assessment of the quality of patient-reported medical information in the Dutch Biologic Monitor and evaluation of the representativeness of the sampled participants. METHODS: Consecutive adult patients using a biologic DMARD (bDMARD) for an immune-mediated inflammatory disease were included in eight Dutch centres. For this substudy, data of 550 patients with inflammatory rheumatic diseases were used. Patient-reported bDMARD prescription, indication and combination therapy were verifi...
#1Ylenia Ingrasciotta (UNIME: University of Messina)H-Index: 13
Last. Gianluca Trifirò (UNIME: University of Messina)H-Index: 40
view all 6 authors...
In recent years, marketing of highly innovative and costly biologics improved the management of high-burden diseases such as autoimmune diseases, cancers, and chronic renal failure. Several widely prescribed biologics have recently lost or will shortly lose their patents, thus opening avenues to the marketing of a growing number of biosimilars worldwide, which are products similar in terms of quality, safety, and efficacy to already licensed reference products, thus allowing for potential saving...
#1Leticia Leon (Universidad Camilo José Cela)H-Index: 15
#2Ana Isabel Gómez (Hospital Clínico San Carlos)H-Index: 3
Last. Lydia Abasolo (Hospital Clínico San Carlos)H-Index: 21
view all 7 authors...
Abstract Biological DMARDs are widely used in the treatment of rheumatoid arthritis (RA) but their relationship with adverse drug reaction (ADR) is important. RA is now known to increase in incidence and prevalence with age. Our objective was to assess the incidence of severe ADR in the long term, compare safety between the different bDMARDs and identify other possible risk factors for severe ADR in elderly RA patients. A 14-year retrospective longitudinal study was performed. RA patients follow...
#1J. Helby (UCPH: University of Copenhagen)H-Index: 2
Last. Stig E. BojesenH-Index: 90
view all 4 authors...
Background Individuals with atopic conditions may have increased susceptibility to infections outside the organs directly affected by their atopic condition. Objective We tested the hypothesis that atopic conditions overall, and stratified by smoking history, are associated with increased risk of hospitalization for infections. Methods We collected information on smoking history and self-reported atopic conditions from 105 519 individuals from the general population and followed them for up to 2...
#2Irene PontikakiH-Index: 21
Last. Pier Luigi Meroni (University of Milan)H-Index: 102
view all 11 authors...
The aim of this study is to retrospectively analyze 10-year drug survival of first-line TNF inhibitor (TNFi) in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA) patients, comparing withdrawal rates and discontinuation pattern between adult- and juvenile-onset populations. RA, AS, PsA, and JIA patients treated with infliximab, etanercept, or adalimumab as first TNFi between 1999 and 2015 were extracted from a local registry...
#1Bárbara P. Fafá (UFES: Universidade Federal do Espírito Santo)H-Index: 1
#2Paulo Louzada-Junior (USP: University of São Paulo)H-Index: 27
Last. Valeria Valim (UFES: Universidade Federal do Espírito Santo)H-Index: 20
view all 34 authors...
Treatment survival with biological therapy may be influenced by many factors, and it seems to be different among various rheumatic diseases and biological agents. The goal of the study was to compare the drug survival and the causes of discontinuation of anti-tumoral necrosis factor (anti-TNF) therapy in ankylosing spondylitis (AS) with rheumatoid arthritis (RA). Study participants were a cohort from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (BIOBADABRASIL) between 200...
Biologicals are often thought to increase the risk of infection. A recent review shows that the risk of serious infection in patients with rheumatoid arthritis being treated with biologicals (standard dose) is only mildly elevated compared with those who are treated with conventional DMARDs only (odds ratio: 1.3). If biologicals are used at a lower dosage, e.g. tapering studies, the risk of serious infection does not seem to be increased. Alertness for infection in these patients, dose tapering ...
#1Chi Chiu Mok (Tuen Mun Hospital)H-Index: 68
#2Ka Yan Chan (Kowloon Hospital)H-Index: 1
Last. Ka Wing LeeH-Index: 1
view all 5 authors...
Objectives To study the factors associated with withdrawal of the and tumor necrosis factor alpha (anti-TNFα) biologics in the treatment of rheumatic diseases. Method Data from the Hong Kong Biologics Registry were retrieved. The cumulative rates of withdrawal of different biological agents were studied by Kaplan–Meier plot and the incidence of serious adverse events (SAEs) was calculated. Factors associated with the withdrawal of the anti-TNFα agents were studied by Cox regression. Results Betw...
Introduction: Advances in biomedical technology and access to effective medications have resulted in significant improvements in patient survival and quality of life. Patient adherence is crucial to quality healthcare outcomes; however, achievement of consistent adherence remains difficult. Patient non-adherence represents an important health problem, from a clinical/economic viewpoint, being associated with reduced treatment benefits and significant financial burden. Non-adherence potentially l...
Cited By4
OBJECTIVE We aimed to describe the nature and frequency of gastrointestinal adverse drug reactions (GI-ADRs) of etanercept (ETN) using patient-reported and healthcare professional (HCP)-registered data and compared this frequency with the GI-ADR frequency of the widely used TNFα-inhibitor adalimumab. METHODS Reported GI-ADRs of ETN for rheumatic diseases were collected from the Dutch Biologic Monitor and DREAM registries. We described the clinical course of GI-ADRs and compared the frequency wit...
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 2
#2Tessa E H Römkens (Bosch)H-Index: 14
Last. Frank Hoentjen (Radboud University Nijmegen)H-Index: 18
view all 8 authors...
BACKGROUND Only limited data is available on the extent and burden of adverse drug reactions (ADRs) to biological therapy in inflammatory bowel disease (IBD) patients in daily practice, especially from a patient's perspective. OBJECTIVE The aim of this study was to systematically assess patient-reported ADRs during biological therapy in IBD patients and compare these with healthcare provider (HCP)-reported ADRs. METHODS This multicentre, prospective, event monitoring study enrolled IBD patients ...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel coronavirus disease 2019 (COVID-19) pandemic that lacks globally accessible effective antivirals or extensively available vaccines. Numerous clinical trials are exploring the applicability of repurposed monoclonal antibodies (mAbs) targeting cytokines that cause adverse COVID-19-related pathologies, and novel mAbs directly targeting SARS-CoV-2. However, comorbidities and the incidence of cytokine...
#1Florence van HunselH-Index: 15
#2Emma de Jong (UU: Utrecht University)H-Index: 2
Last. Jarno Hoekman (UU: Utrecht University)H-Index: 18
view all 4 authors...
PURPOSE The aim of the study is to characterise safety signals based on the Dutch spontaneous reporting system (SRS) and to investigate the association between signal characteristics and Product Information (PI) update stratified by approval type: centrally authorised products (CAPs) versus nationally and decentralised authorised products (NAPs). METHODS This study evaluates the full cohort of signals disseminated from the Dutch SRS in the period from 2008 to 2017. Each retrieved signal was char...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.